CTRI/2012/05/002651
Not Yet Recruiting
N/A
Evaluation of Immunological Markers for monitoring of Neonatal sepsis.
BECTION DICKINSON AND COMPANY0 sites100 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- BECTION DICKINSON AND COMPANY
- Enrollment
- 100
- Status
- Not Yet Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Term or Pre\-term neonates (born at greater than 28 weeks gestation) admitted to neonatal intensive care units, presenting with signs and symptoms suggestive of systemic infection and requiring a full sepsis evaluation and antibiotic treatment will be eligible for inclusion in the study irrespective of their birth weight and postnatal age.
Exclusion Criteria
- •Patients who were already receiving parenteral antibiotics at time of initial sepsis evaluation will be excluded
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Immunological monitoring and assessment of biomarkers predictive of clinical response to first-line treatment with bosutinib or imatinib in chronic phase chronic myeloid leukemiaChronic myeloid leukemiaCML10024324NL-OMON42791Vrije Universiteit Medisch Centrum5
Not Yet Recruiting
N/A
Immunohematogical markers in Graves diseaseHealth Condition 1: E050- Thyrotoxicosis with diffuse goiterCTRI/2021/12/038899Jayanthy Ramesh
Recruiting
N/A
Detection of markers for immune pathophysiology and analysis of their prognostic value in patients with chronic thrombocytopenia without an increase in the number of bone marrow megakaryocytes: a prospective observation study.Pancytopenia, thrombocytopeniaJPRN-UMIN000002729Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science.50
Active, Not Recruiting
Phase 1
Monitoring response on COVID-19 vaccination in children with cancerChildren with cancer, receiving COVID-19 vaccinationTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2021-003388-90-NLPrincess Máxima Center for Pediatric Oncology130
Completed
Phase 4
Prospective monitoring of immune response following COVID-19 vaccination in children with cancerNL-OMON52106Prinses Máxima Centrum voor Kinderoncologie130